09:23 uur 01-09-2015

Y-STRUT van Hyprevention krijgt CE-markering

PESSAC, France–(BUSINESS WIRE)– Hyprevention heeft een CE-markering gekregen voor Y-STRUT, een implanteerbaar medisch apparaat ter preventie van een heupfractuur. Hyprevention is nu beschikbaar voor commerciële inzet in Europa.


Y-STRUT is een te implanteren medisch apparaat dat fracturen in het dijbeen voorkomt. Het is bedoeld voor twee klinische indicaties. 

  • Traumatologie, voor contralaterale, percutane, interne bevestigingen aan het dijbeen bij patiënten met heupfractuur.
  • Oncologie, percutane interne bevestiging voor een dreigende pathologische fractuur in het dijbeen. Laatste middel.


Y-STRUT® by Hyprevention® : CE Mark Obtained


PESSAC, France–(BUSINESS WIRE)– Hyprevention ® receives CE Mark approval for Y-STRUT ® , an implantable medical device designed to prevent hip fracture. Hyprevention ® isnow ready for commercial deployment in Europe.

About Y-STRUT ®

Y-STRUT ® is an implantable medical device indicated to prevent fractures of the proximal femur. It is intended to be used in two clinical indications:

  • Traumatology, for contralateral percutaneous internal fixation of proximal femur, in patient with a low energy pertrochanteric fracture on the first side,
  • Oncology, for percutaneous internal fixation for impending pathological fracture of proximal femur. Act of last resort (ultima ratio).

Y-STRUT ® is implanted thanks to a minimally invasive procedure by an orthopedic surgeon or an interventional radiologist.

14 patients already successfully benefited from Y-STRUT ® technology in the clinical trials jointly conducted at the University Hospital of Bordeaux, the Gustave Roussy Institute in Paris and at the University Hospital Brugmann in Brussels.

Y-STRUT ® development was supported by BPIFrance and the Regional Council of Aquitaine.

About Hyprevention ®

Founded in 2010 by Cécile Vienney (CEO) and 3 orthopedic surgeons, Hyprevention is a French company that develops, manufactures and sells implantable medical devices to address unmet clinical needs. It is certified ISO 13485: 2003 since January 2014, and CMDCAS since January 2015.


Cécile Vienney, +33 (0)5 57 10 28 52

Check out our twitter: @NewsNovumpr